1. Protein Tyrosine Kinase/RTK
    Autophagy
  2. VEGFR
    PDGFR
    Autophagy

Sunitinib (Synonyms: SU 11248)

Cat. No.: HY-10255A Purity: 99.56%
Data Sheet SDS Handling Instructions

Sunitinib is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.

For research use only. We do not sell to patients.
Sunitinib Chemical Structure

Sunitinib Chemical Structure

CAS No. : 557795-19-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
100 mg $50 In-stock
200 mg $80 In-stock
500 mg $95 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Sunitinib:

    Sunitinib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

    Sunitinib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

    Sunitinib purchased from MCE. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72.

    Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Sunitinib is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.

    IC50 & Target

    IC50: 2 nM (PDGFRβ), 80 nM (VEGFR2)[1]

    In Vitro

    Sunitinib Malate is also a good inhibitor of KIT and FLT-3[1]. In biochemical assays, Sunitinib (SU11248) exhibits competitive inhibition (with regard to ATP) against Flk-1 and PDGFRβ with Ki values of 9 nM and 8 nM, respectively. Sunitinib is also a competitive, albeit less potent, inhibitor of FGFR1 tyrosine kinase activity, with a Ki value of 0.83 μM. In addition to these three structurally related split kinase domain RTKs, the activity of Sunitinib has also been evaluated against a broad panel of additional tyrosine and serine/threonine kinases. In these biochemical assays, the IC50 values for Sunitinib are generally at least 10-fold higher than those for Flk-1 and PDGFR (e.g., IC50values of: >10 μM for EGFR and Cdk2; 4 μM for Met; 2.4 μM for IGFR-1; 0.8 μM for Abl; and 0.6 μM for Src)[2]. In RS4;11 cells (FLT3-WT), treatment with Sunitinib (SU11248) inhibits FLT3-WT phosphorylation in a dose-dependent manner with IC50 of approximately 250 nM. In MV4;11 cells that express FLT3-ITD, Sunitinib inhibits FLT3-ITD phosphorylation in a dose-dependent manner with an IC50 of 50 nM following a 2-hour treatment[3].

    In Vivo

    Sunitinib Malate has very good oral bioavailability, is highly efficacious in a number of preclinical tumor models, and is well tolerated at efficacious doses[1]. Sunitinib (80 mg/kg/day) inhibits the growth of established SF763T and Colo205 tumor xenografts in athymic mice. Sunitinib (SU11248) treatment effectively inhibits the growth of established tumor xenografts[2]. Sunitinib malate is an inhibitor of VEGFR, PDGFR, FGFR, and is used in the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib malate-treated rats display much lower levels of tumor growth than untreated rats, and their tumors have much smaller necrotic areas and lower vascular density[4].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00794950 University of Michigan Urinary Tract Urothelial Carcinoma January 2009 Phase 2
    NCT01499121 Sunnybrook Health Sciences Centre|Pfizer Clear Cell, Metastatic Renal Cell Carcinoma May 2012 Phase 2
    NCT01498835 Heidelberg University|German Research Foundation Soft Tissue Sarcoma February 2012 Phase 1
    NCT00886132 University Health Network, Toronto Adenoid Cystic Carcinoma|Salivary Gland Cancer January 2007 Phase 2
    NCT02626754 vghtpe user|Taipei Veterans General Hospital, Taiwan Renal Cell Carcinoma August 2015 Phase 2
    NCT00912912 M.D. Anderson Cancer Center|Pfizer Genitourinary Disease May 2009 Phase 2
    NCT00422344 Memorial Sloan Kettering Cancer Center|Novartis Renal Cell Carcinoma|Kidney Cancer October 2006 Phase 1
    NCT00768144 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer September 2008 Phase 2
    NCT02398552 Beijing Cancer Hospital Metastatic Renal Cell Carcinoma March 2015 Phase 2
    NCT00864864 Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Pfizer Glioblastoma|Brain Tumor May 2007 Early Phase 1
    NCT00961571 Georgetown University|Pfizer Metastatic Colorectal Cancer August 2009 Phase 2
    NCT00672594 Duke University|Pfizer Prostate Cancer|Prostatectomy July 2006 Phase 2
    NCT02713763 Grupo Espanol de Tumores Neuroendocrinos Pancreatic Neuroendocrine Tumour Metastatic April 2016 Phase 2
    NCT00606008 H. Lee Moffitt Cancer Center and Research Institute|Pfizer Anaplastic Astrocytoma|Glioblastoma March 2007 Phase 2
    NCT03109015 Duke University Carcinoma, Renal Cell August 2017 Phase 2
    NCT01286896 The Netherlands Cancer Institute|Pfizer Malignant Solid Tumour March 2011 Phase 1
    NCT02058901 VU University Medical Center Solid Tumors July 2013 Phase 1
    NCT00663559 Spanish Oncology Genito-Urinary Group Carcinoma Renal Cells February 2008 Phase 2
    NCT01082809 Samsung Medical Center Advanced Biliary Tract Adenocarcinoma March 2009 Phase 2
    NCT01308034 Centre Leon Berard|Ministry of Health, France Non GIST Sarcomas March 2011 Phase 1
    NCT00556205 Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Pfizer Renal Cell Carcinoma September 2009 Phase 2
    NCT01073644 Pfizer Metastatic Renal Cell Carcinoma February 2010 Phase 4
    NCT01824615 Cathay General Hospital Ovarian Cancer|Adverse Effects January 2013 Phase 2
    NCT01122615 M.D. Anderson Cancer Center|Pfizer Renal Cell Cancer|Kidney Cancer May 2010 Phase 1
    NCT00753727 Australasian Sarcoma Study Group|Peter MacCallum Cancer Centre, Australia|Pfizer Soft Tissue Sarcoma September 2008 Phase 1|Phase 2
    NCT00981890 University Health Network, Toronto Brain Metastases July 2009 Phase 1
    NCT03066427 Spanish Oncology Genito-Urinary Group Clear Cell Renal Carcinoma May 10, 2017 Phase 2
    NCT00967603 IRCCS San Raffaele Pancreatic Cancer February 2008 Phase 2
    NCT00616109 University of Michigan Cancer Center Extensive-Stage Small Cell Lung Cancer September 2007 Phase 2
    NCT00843037 University Health Network, Toronto|Pfizer Paraganglioma|Pheochromocytoma February 2009 Phase 2
    NCT01100177 Grupo Español de Investigación en Neurooncología Glioblastoma June 2009 Phase 2
    NCT00465179 M.D. Anderson Cancer Center|Pfizer Renal Cell Cancer|Kidney Cancer March 2007 Phase 2
    NCT00818350 Campania Younger Oncologists Association Urinary Bladder Neoplasms January 2009 Phase 1|Phase 2
    NCT01034878 Istituto Clinico Humanitas Carcinoma, Renal Cell December 2009 Phase 2
    NCT00480935 University Health Network, Toronto|Pfizer Renal Cell Carcinoma October 2007 Phase 2
    NCT00706706 Pfizer Carcinoma, Renal Cell July 2008 Phase 4
    NCT02919371 King Faisal Specialist Hospital & Research Center Renal Cell Carcinoma December 2014 Phase 1|Phase 2
    NCT00510640 University Hospital, Bordeaux|Pfizer Cancer|Thyroid Carcinoma August 2007 Phase 2
    NCT00299741 Massachusetts General Hospital|United States Department of Defense Prostate Cancer March 2006 Phase 2
    NCT03140176 Pfizer Metastatic Renal Cell Carcinoma June 30, 2017
    NCT01718327 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Unresectable and Advanced Cholangiocarcinoma September 1, 2011 Phase 2
    NCT00400569 H. Lee Moffitt Cancer Center and Research Institute|Pfizer Liposarcoma|Leiomyosarcoma|Fibrosarcoma|Malignant Fibrous Histiocytoma November 2006 Phase 2
    NCT00796861 Milton S. Hershey Medical Center Ascites May 2007 Phase 2
    NCT00702884 Tony Bekaii-Saab|Pfizer|Ohio State University Comprehensive Cancer Center Esophageal Cancer June 30, 2008 Phase 2
    NCT00673816 National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) Von Hippel-Lindau Syndrome May 2008 Phase 1|Phase 2
    NCT00599313 US Oncology Research|Pfizer Metastatic Prostate Cancer March 2007 Phase 2
    NCT00459979 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Kidney Cancer March 2007 Phase 2
    NCT00821327 US Oncology Research|Pfizer Urothelial Cancer August 2008 Phase 2
    NCT00556049 Massachusetts General Hospital|Pfizer|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute Renal Cell Carcinoma|Neoplasm Metastases December 2007 Phase 2
    NCT01064310 Novartis Pharmaceuticals|Novartis Carcinoma, Renal Cell May 17, 2010 Phase 3
    NCT01054911 University of Alabama at Birmingham|Pfizer Tumor October 2009
    NCT02386111 Celldex Therapeutics Carcinoma, Renal Cell|Kidney Diseases|Kidney Neoplasms|Urogenital Neoplasms|Urologic Diseases|Urologic Neoplasms|Neoplasms|Neoplasms by Histologic Type|Clear-cell Metastatic Renal Cell Carcinoma May 2015 Phase 1|Phase 2
    NCT00788060 Daniel George, MD|Novartis|Pfizer|Duke University Renal Cell Carcinoma October 2008 Phase 1
    NCT01216657 Krankenhaus Nordwest Chemo-refractory Melanoma March 2009 Phase 2
    NCT00397787 National Cancer Institute (NCI) Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer November 2006 Phase 2
    NCT01069770 Korean Urological Oncology Society|Pfizer Clear Cell Renal Cell Carcinoma|Metastasis July 2009 Phase 2
    NCT01827254 Pfizer Metastatic Renal Cell Carcinoma July 2013
    NCT00437372 Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University Cancer|Head and Neck Cancer|Pelvic Cancer|Nervous System Neoplasms|Thoracic Neoplasms March 2007 Phase 1
    NCT01517243 Dartmouth-Hitchcock Medical Center Metastatic Renal Cell Carcinoma June 2010 Phase 2
    NCT00392444 National Cancer Institute (NCI) Advanced Malignant Mesothelioma|Recurrent Malignant Mesothelioma February 2007 Phase 2
    NCT02402062 Grupo Espanol de Tumores Neuroendocrinos|Threshold Pharmaceuticals|Pfizer Neuroendocrine Tumors|Pancreatic Neoplasms February 2015 Phase 2
    NCT00980213 Pirkko-Liisa Kellokumpu-Lehtinen|University of Turku|Oulu University Hospital|Tampere University Hospital Neoplasms|Renal Cell Carcinoma September 2009
    NCT00378911 National Cancer Institute (NCI) Recurrent Uterine Sarcoma|Uterine Leiomyosarcoma October 2006 Phase 2
    NCT03025893 VU University Medical Center Glioblastoma Multiforme|Glioblastoma, Adult|Glioblastoma|Recurrent Brain Tumor|GBM June 2017 Phase 2|Phase 3
    NCT02691793 Samsung Medical Center Refractory Solid Tumors April 2017 Phase 4
    NCT00389974 National Cancer Institute (NCI) Cervical Adenocarcinoma|Cervical Adenosquamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Cancer|Stage IVB Cervical Cancer January 2007 Phase 2
    NCT00520533 Ludwig Institute for Cancer Research|Pfizer|Wilex Renal Cell Carcinoma February 2008
    NCT01219751 Asan Medical Center|Samsung Medical Center|Seoul National University Hospital|Kyungpook National University Metastatic Renal Cell Carcinoma June 2008 Phase 2
    NCT01551459 The Clatterbridge Cancer Centre NHS Foundation Trust|Cancer Research UK|Pfizer Metastatic Uveal Melanoma October 2010 Phase 2
    NCT00577382 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Pfizer Mucosal Lentiginous Melanoma|Acral Lentiginous Malignant Melanoma August 2007 Phase 2
    NCT00372775 Pfizer Non-Small Cell Lung Cancer March 2007 Phase 2
    NCT00715442 M.D. Anderson Cancer Center|Pfizer Renal Cell Carcinoma June 2008 Phase 2
    NCT00570882 Asan Medical Center Metastatic Renal Cell Carcinoma October 2007 Phase 2
    NCT00519896 University of Washington|National Cancer Institute (NCI) Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma July 2007 Phase 2
    NCT00338884 Pfizer Carcinoma, Renal Cell September 2006 Phase 2
    NCT01020630 PD Dr Markus Möhler|Johannes Gutenberg University Mainz Adenocarcinoma November 2009 Phase 2
    NCT02164240 Dana-Farber Cancer Institute|Bayer|Pfizer Gastrointestinal Stromal Tumor July 2014 Phase 1
    NCT01061411 Roswell Park Cancer Institute|National Cancer Institute (NCI)|Pfizer Clear Cell Sarcoma of the Kidney|Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer February 6, 2010 Phase 1
    NCT00478426 National Cancer Institute (NCI) Endometrial Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer|Uterine Carcinosarcoma|Uterine Corpus Carcinosarcoma April 30, 2007 Phase 2
    NCT00581789 University of Wisconsin, Madison|Pfizer|Genentech, Inc. Non Small Cell Lung Cancer August 2007 Phase 1
    NCT01481870 Yamagata University Metastatic Renal Cell Carcinoma January 2010 Phase 3
    NCT00471276 Pfizer Breast Neoplasms August 2007 Phase 2
    NCT00421512 Memorial Sloan Kettering Cancer Center Metastatic Renal Cell Carcinoma|Kidney Cancer March 2006 Phase 1
    NCT02060370 M.D. Anderson Cancer Center|Pfizer Genitourinary Cancer|Kidney Cancer August 2014 Phase 2
    NCT02928575 Bassam Abdulkarim|Pfizer|Canadian Cancer Society Research Institute (CCSRI)|McGill University Health Center Glioblastoma Multiforme August 2012 Phase 2
    NCT00793871 Pfizer Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors November 2008 Phase 4
    NCT00631618 California Pacific Medical Center Research Institute|Pfizer|University of California, San Francisco Metastatic Melanoma September 2007 Phase 2
    NCT01070706 Jungsil Ro|Pfizer|CJ HealthCare Corporation|National Cancer Center, Korea Breast Cancer March 2009 Phase 1|Phase 2
    NCT00910039 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Cognitive/Functional Effects|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific April 2009 Phase 2
    NCT03097601 Centre Antoine Lacassagne|Institut National de la Santé Et de la Recherche Médicale, France Metastatic Kidney Cancers June 2, 2016
    NCT02623127 Seoul National University Hospital|SMG-SNU Boramae Medical Center Thymic Carcinoma October 2015 Phase 2
    NCT00388037 National Cancer Institute (NCI) Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian January 2007 Phase 2
    NCT00795171 Medical University of Vienna Hormone Refractory Prostate Cancer November 2008 Phase 2
    NCT00514228 Swiss Group for Clinical Cancer Research Liver Cancer July 2007 Phase 2
    NCT01391962 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sarcoma, Alveolar Soft Part June 17, 2011 Phase 2
    NCT00329043 M.D. Anderson Cancer Center|Pfizer Prostate Cancer May 2006 Phase 2
    NCT02074878 Mothaffar Rimawi|Baylor Breast Care Center Breast Cancer June 2014 Phase 1
    NCT00495625 H. Lee Moffitt Cancer Center and Research Institute|Pfizer Liver Cancer October 2006 Phase 2
    NCT00890747 National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia W August 2009 Phase 1
    NCT00526656 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Bladder Cancer September 2007 Phase 2
    NCT00434109 H. Lee Moffitt Cancer Center and Research Institute|Pfizer Neuroendocrine Tumor|Islet Cell Tumor November 2006 Phase 2
    NCT00716625 Pfizer Carcinoma, Renal Cell June 2008
    NCT02432846 Immunicum AB|TFS Trial Form Support|Accelovance Renal Cell Carcinoma, Metastatic April 2015 Phase 2
    NCT01743300 Leiden University Medical Center Healthy July 2007 Phase 1
    NCT01525550 Pfizer Well-differentiated Pancreatic Neuroendocrine Tumor June 6, 2012 Phase 4
    NCT00387426 National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phas September 2006 Phase 2
    NCT01042795 University of Michigan|Pfizer Urothelial Carcinoma|Bladder Cancer September 2009 Phase 2
    NCT02071641 VU University Medical Center Metastatic Renal Cell Carcinoma October 2012 Phase 2
    NCT01168440 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie Von Hippel-Lindau Disease March 2010 Phase 2
    NCT00535379 Medical University Innsbruck|Pfizer Glioblastoma Multiforme October 2007 Phase 2
    NCT00457743 Pfizer Gastrointestinal Stromal Tumors January 2005 Phase 1|Phase 2
    NCT00806663 Central European Society for Anticancer Drug Research Metastatic Colorectal Cancer|Liver Metastases August 2008 Phase 2
    NCT00979992 National Cancer Institute (NCI) Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Carcinoma April 2010 Phase 2
    NCT01121562 Pfizer Pancreatic Neuroendocrine Tumors July 2010 Phase 2
    NCT01850147 Chinese Academy of Medical Sciences Cancer|Lung Cancer March 2013 Phase 2
    NCT00514137 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma September 2007 Phase 2
    NCT00813423 National Cancer Institute (NCI) Adult Solid Neoplasm January 27, 2010 Phase 1
    NCT00444314 CASI Pharmaceuticals, Inc. Metastatic Renal Cell Carcinoma February 2007 Phase 2
    NCT01402817 Indiana University|United States Department of Defense|Pfizer Neurofibromatosis|NF1|Plexiform Neurofibromas March 2012 Phase 2
    NCT00453895 University of Wuerzburg|Pfizer Adrenocortical Carcinoma July 2007 Phase 2
    NCT00387335 National Cancer Institute (NCI) Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Squamous Cel August 2006 Phase 2
    NCT00716820 Pfizer Gastrointestinal Stromal Tumors May 2008
    NCT01621568 National Cancer Institute (NCI)|Indiana University School of Medicine|National Institutes of Health Clinical Center (CC) Thymoma|Thymus Neoplasms April 18, 2012 Phase 2
    NCT03075423 Lothar Bergmann|Johann Wolfgang Goethe University Hospital Metastatic Renal Cell Carcinoma April 1, 2017 Phase 2
    NCT00732992 Pfizer Neoplasm, Malignant August 2008 Phase 1
    NCT01673386 AVEO Pharmaceuticals, Inc.|Astellas Pharma Inc Metastatic Renal Cell Carcinoma July 2012 Phase 2
    NCT00499473 National Cancer Institute (NCI) Adult Anaplastic Astrocytoma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Pineal Gland Astrocytoma June 2007 Phase 2
    NCT00884676 Jaime Merchan|Bristol-Myers Squibb|Pfizer|University of Miami Unspecified Adult Solid Tumor, Protocol Specific November 2008 Phase 1
    NCT00451048 National Cancer Institute (NCI) Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndromes|Secondary Myelodysplastic Syndromes February 2007 Phase 2
    NCT00729833 Pfizer Advanced Cancer|Advanced Solid Tumors September 2008 Phase 1
    NCT00787787 University of Washington|National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer September 2008 Phase 2
    NCT00397488 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pfizer Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer September 2006 Phase 2
    NCT00425386 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Kidney Cancer August 2006 Phase 2
    NCT02684006 Pfizer Renal Cell Cancer March 23, 2016 Phase 3
    NCT00459875 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Kidney Cancer March 2007 Phase 2
    NCT00113529 Pfizer Carcinoma, Renal Cell October 2004 Phase 1|Phase 2
    NCT01147822 Novartis Pharmaceuticals|Novartis Carcinoma, Renal Cell May 19, 2010 Phase 2
    NCT00392496 National Cancer Institute (NCI) Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma February 2007 Phase 2
    NCT00247676 Pfizer Liver Neoplasms|Unresectable Hepatocellular Carcinoma February 2006 Phase 2
    NCT02068586 Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University Ciliary Body and Choroid Melanoma, Medium/Large Size|Ciliary Body and Choroid Melanoma, Small Size|Iris Melanoma|Stage I Intraocular Melanoma|Stage IIA Intraocular Melanoma|Stage IIB Intraocular Melanoma|Stage IIIA Intraocular Melanoma|Stage IIIB Intraocular Melanoma|Stage IIIC Intraocular Melanoma November 2014 Phase 2
    NCT00694096 University of Utah|National Comprehensive Cancer Network Renal Cell Cancer September 2007 Phase 1
    NCT01185366 M.D. Anderson Cancer Center|Novartis Kidney Cancer August 2010 Phase 2
    NCT00453310 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pfizer Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor March 2007 Phase 2
    NCT01238055 Samsung Medical Center Advanced Gastric Cancer November 2008 Phase 2
    NCT01548170 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Cancer April 2011 Phase 1
    NCT00496223 H. Lee Moffitt Cancer Center and Research Institute|Pfizer Melanoma September 2006 Phase 1|Phase 2
    NCT00056693 Pfizer Neuroendocrine Tumors April 2003 Phase 2
    NCT03035630 Guru Sonpavde|Hoosier Cancer Research Network|Pfizer Clear-cell Renal Cell Carcinoma|RCC|Kidney Cancer|Clear-cell Kidney Carcinoma July 2017 Phase 2
    NCT00092001 Pfizer Carcinoma, Non-Small-Cell Lung January 2005 Phase 2
    NCT01309633 National University Hospital, Singapore Nasopharyngeal Carcinoma September 2011 Phase 2
    NCT00699374 Pfizer Carcinoma, Hepatocellular July 2008 Phase 3
    NCT02400385 California Pacific Medical Center Research Institute|Pfizer Melanoma October 2014 Phase 2
    NCT02282059 Pfizer Pancreatic Neuroendocrine Tumors December 12, 2014
    NCT01462695 National Cancer Institute (NCI) Childhood Cerebellar Anaplastic Astrocytoma|Childhood Cerebral Anaplastic Astrocytoma|Childhood Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma January 2012 Phase 2
    NCT00720148 Emory University|Millennium Pharmaceuticals, Inc.|Pfizer Solid Tumors February 2008 Phase 1
    NCT00930033 Assistance Publique - Hôpitaux de Paris|Pfizer Metastatic Renal Cell Carcinoma September 2009 Phase 3
    NCT00783653 Universitätsklinikum Hamburg-Eppendorf Acute Myeloid Leukemia August 2008 Phase 1|Phase 2
    NCT02446795 Consorzio Oncotech|Clinical Research Technology S.r.l.|Quercegen Pharmaceuticals Renal Cell Carcinoma|Kidney Cancer November 2016 Phase 1|Phase 2
    NCT00428220 Pfizer Metastatic Breast Cancer [F]|Advanced Breast Cancer|Metastatic Castration Resistant Prostate Cancer|Metastatic Renal Cell Cancer|Non-Small Cell Lung Cancer|Thyroid Cancer|Advanced/Metastatic Non-Small Cell Lung Cancer|Advanced Gastric Cancer|Gastrointestinal Stromal Tumor|Hepatocellular Carcinoma|Pancreatic Islet Cell Carcinoma|Pancreatic Neuroendocrine Tumor July 2007
    NCT01265901 immatics Biotechnologies GmbH Metastatic Renal Cell Carcinoma December 2010 Phase 3
    NCT00975806 Celgene Renal Cell Carcinoma September 2009 Phase 1|Phase 2
    NCT00903175 Novartis Pharmaceuticals|Novartis Renal Cell Carcinoma October 2009 Phase 2
    NCT00620347 National Cancer Center, Korea|Pfizer Lung Cancer March 2008 Phase 2
    NCT00695292 SCRI Development Innovations, LLC|Pfizer Small Cell Lung Cancer June 2008 Phase 2
    NCT00853372 Amgen Advanced Renal Cell Carcinoma May 28, 2009 Phase 2
    NCT01396148 Pfizer Gastrointestinal Stromal Tumors June 25, 2012 Phase 2
    NCT00543049 AGO Study Group|Philipps University Marburg Medical Center|HSK Reasearch GmbH Wiesbaden Platinum Refractory Epithelial Ovarian Cancer|Primary Cancer of the Peritoneum|Cancer of the Fallopian Tube September 2007 Phase 2
    NCT00381641 National Cancer Institute (NCI) Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Medullary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland P August 2006 Phase 2
    NCT00747305 Harry Drabkin|Medical University of South Carolina Kidney Cancer October 2008 Phase 1
    NCT01033981 Pfizer Metastatic Renal Cell Carcinoma May 2010 Phase 4
    NCT00555256 Washington University School of Medicine|Pfizer Non-Small Cell Lung Cancer November 2007 Phase 1
    NCT00528619 Pfizer Neoplasms November 2006 Phase 1
    NCT00357318 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific June 2006 Phase 1
    NCT00399152 AEterna Zentaris Renal Cancer|GIST October 2006 Phase 1
    NCT01506336 AB Science Gastro Intestinal Stromal Tumor October 2008 Phase 2
    NCT00656669 Indiana University|Pfizer Breast Cancer April 2008
    NCT00859456 Columbia University Sarcoma, Soft Tissue April 2007 Phase 2
    NCT02555748 Institut Claudius Regaud|University Hospital, Bordeaux Metastatic Renal Cell Cancer October 2015 Phase 4
    NCT01803503 National University Hospital, Singapore Solid Tumors|Breast Cancer|Non-small Cell Lung Cancer|Prostate Cancer|Gastric Cancer May 2013 Phase 2
    NCT00887575 SCRI Development Innovations, LLC|Pfizer Breast Cancer June 2009 Phase 1|Phase 2
    NCT00720941 Novartis Pharmaceuticals|Novartis Carcinoma, Renal Cell August 14, 2008 Phase 3
    NCT01829217 Dana-Farber Cancer Institute Lung Cancer May 2013 Phase 2
    NCT00417885 Pfizer Breast Neoplasms June 2007 Phase 1|Phase 2
    NCT02689167 Centre Hospitalier Universitaire de Besancon|Pfizer Kidney Neoplasms|Metastatic Renal Cell Cancer February 2016 Phase 2
    NCT00609622 Pfizer Colorectal Neoplasms April 2008 Phase 2
    NCT01402089 Markus Joerger|University of Basel|Cantonal Hospital of St. Gallen Non Small-cell Lung Cancer|Renal-cell Cancer|Gastrointestinal Stroma Tumor January 2012 Phase 4
    NCT00589784 Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|University of Virginia|University of Pittsburgh|Pfizer CNS Cancer|Meningioma|Intracranial Hemangiopericytoma|Hemangioblastoma|Neurofibromatosis October 2007 Phase 2
    NCT00326898 National Cancer Institute (NCI)|ECOG-ACRIN Cancer Research Group|NCIC Clinical Trials Group|Southwest Oncology Group|Cancer and Leukemia Group B Stage I Renal Cell Cancer|Stage II Renal Cell Cancer|Stage III Renal Cell Cancer April 2006 Phase 3
    NCT01731925 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Pfizer|Ipsen Carcinoid Tumors January 7, 2013 Phase 2
    NCT00824538 University of California, San Francisco|National Cancer Institute (NCI) Breast Cancer February 2009 Phase 2
    NCT00550810 Alberta Health Services|Pfizer|AHS Cancer Control Alberta Prostate Cancer|Hormone Refractory October 2007 Phase 2
    NCT00668863 Pfizer Unresectable or Metastatic Colorectal Cancer May 2008 Phase 2
    NCT00462982 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Kidney Cancer|Melanoma (Skin)|Metastatic Cancer March 2007 Phase 2
    NCT01108445 Duke University|Novartis|Pfizer Advanced Non-clear Cell Renal Cell Carcinoma September 2010 Phase 2
    NCT01070186 Jonsson Comprehensive Cancer Center|Pfizer Renal Cell Carcinoma October 2010 Phase 2
    NCT00853125 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey Kidney Cancer February 2009 Phase 2
    NCT01740154 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Fatigue|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer September 2012
    NCT00814021 Institut Claudius Regaud Kidney Cancer|Metastatic Cancer April 2009 Phase 2
    NCT01019798 Taipei Medical University Hospital|Pfizer|TTY Biopharm Non Small Cell Lung Cancer January 2009 Phase 2
    NCT00375674 Pfizer Kidney Neoplasms August 2007 Phase 3
    NCT00462553 National Cancer Institute (NCI) Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific March 2007 Phase 1
    NCT00847015 Memorial Sloan Kettering Cancer Center|Pfizer Bladder Cancer|Urinary Bladder February 2009 Phase 2
    NCT00524186 Roswell Park Cancer Institute|Pfizer Esophageal Cancer|Gastric Cancer May 2007 Phase 1
    NCT01835158 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer July 8, 2013 Phase 2
    NCT02420821 Hoffmann-La Roche Renal Cell Carcinoma May 31, 2015 Phase 3
    NCT00521092 National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID) AIDS-related Kaposi Sarcoma|Classic Kaposi Sarcoma January 2009 Phase 2
    NCT01616186 Andrea Harzstark|Novartis|University of California, San Francisco Locally Metastatic Malignant Neoplasm July 2012 Phase 2
    NCT01391130 Eli Lilly and Company Metastatic Clear Cell Renal Cell Carcinoma August 2011 Phase 2
    NCT00583063 University of Chicago|Pfizer Solid Tumors October 2007 Early Phase 1
    NCT00291577 Pfizer Breast Neoplasms July 2006 Phase 1
    NCT00906360 National Cancer Institute (NCI) Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Na July 2008 Phase 1
    NCT01005472 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Metastatic Melanoma December 2008 Phase 1
    NCT00398112 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia August 2007 Phase 2
    NCT00387920 National Cancer Institute (NCI) Central Nervous System Metastases|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Embryonal Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Recurrent Childhood Central Nervous System Embryonal Tumor|Unspecified Childhood Solid Tumor, Protocol Specific October 2006 Phase 1
    NCT01784978 Associació per a la Recerca Oncologica, Spain|Novartis|Pivotal S.L. Metastatic Renal Cell Carcinoma October 2012 Phase 2
    NCT00673504 Central European Society for Anticancer Drug Research Pancreatic Cancer April 2008 Phase 2
    NCT00698815 National Cancer Institute (NCI) Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer April 15, 2008 Phase 2
    NCT01243359 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage I Renal Cell Cancer|Stage II Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Unspecified Adult Solid Tumor, Protocol Specific October 2010 Phase 1
    NCT01024920 Boehringer Ingelheim Carcinoma, Renal Cell December 2009 Phase 2
    NCT02853331 Merck Sharp & Dohme Corp. Renal Cell Carcinoma September 16, 2016 Phase 3
    NCT00372567 Pfizer Gastrointestinal Stromal Tumor June 2007 Phase 3
    NCT01694277 AB Science Gastrointestinal Stromal Tumors April 2012 Phase 3
    NCT01934452 Pfizer Complete Remission in Renal Cell Carcinoma May 21, 2015
    NCT00678119 Argos Therapeutics Renal Cell Carcinoma January 2008 Phase 2
    NCT00798889 Pfizer Solid Tumors March 2004
    NCT00631527 M.D. Anderson Cancer Center|Pfizer Prostate Cancer February 2008 Phase 1
    NCT02231749 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma October 13, 2014 Phase 3
    NCT00511849 Pfizer Neoplasms November 2005 Phase 1
    NCT00522249 The Methodist Hospital System|Schering-Plough Carcinoma, Renal Cell May 2007 Phase 1|Phase 2
    NCT00474994 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute Adult Malignant Fibrous Histiocytoma of Bone|Desmoid Tumor|Endometrial Cancer|Ovarian Cancer|Sarcoma|Small Intestine Cancer April 2007 Phase 2
    NCT00482911 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Intraocular Melanoma|Malignant Conjunctival Neoplasm April 2007 Phase 2
    NCT01472081 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd Renal Cell Carcinoma|Clear-cell Metastatic Renal Cell Carcinoma January 2012 Phase 1
    NCT02790580 National University Hospital, Singapore Breast Cancer May 2016 Phase 2
    NCT00931450 Institut Català d'Oncologia|National Cancer Institute (NCI) Breast Cancer March 2009 Phase 1|Phase 2
    NCT00693992 National Cancer Institute (NCI) Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer June 2008 Phase 3
    NCT00712504 Pfizer Advanced Solid Tumors|Non Small Cell Lung Cancer July 2004 Phase 1
    NCT00676650 Pfizer Prostatic Neoplasms July 2008 Phase 3
    NCT00373113 Pfizer Breast Neoplasms November 2006 Phase 3
    NCT01089088 Wales Cancer Trials Unit|Cardiff University Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer April 2009 Phase 2
    NCT00267748 Pfizer Carcinoma, Renal Cell December 2005 Phase 2
    NCT01164202 Federation Francophone de Cancerologie Digestive Liver Cancer July 2010 Phase 2|Phase 3
    NCT00904657 University of Cologne|University Hospital, Bonn|ZKS Köln Blood Pressure October 2008 Phase 1
    NCT00453154 National Cancer Institute (NCI) Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer March 2007 Phase 1|Phase 2
    NCT01024205 Barts and the London School of Medicine and Dentistry|National Cancer Institute (NCI) Kidney Cancer August 2007 Phase 2
    NCT00393939 Pfizer Breast Neoplasms February 2007 Phase 3
    NCT02450123 Samsung Medical Center Refractory Solid Tumors March 23, 2016
    NCT00631410 Pfizer Colorectal Neoplasms January 2008 Phase 1
    NCT00662025 Pfizer Advanced/Metastatic Breast Cancer April 2008 Phase 2
    NCT00402415 Yale University|Pfizer Tumors February 2006 Phase 1
    NCT02072031 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Anlotinib|RCC December 2013 Phase 2
    NCT00524316 Roswell Park Cancer Institute Liver Cancer April 2007 Phase 2
    NCT00982657 Pfizer Solid Tumor September 2009 Phase 2
    NCT00879619 John P. Fruehauf|Sanofi|University of California, Irvine Prostate Cancer|Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer July 2009 Phase 1|Phase 2
    NCT00430261 Swedish Medical Center|Pfizer Lung Cancer|Adenocarcinoma January 2007 Phase 2
    NCT00372424 Pfizer Breast Cancer December 2006 Phase 1
    NCT00371553 British Columbia Cancer Agency|Canadian Urologic Oncology Group|NCIC Testis Group|German Testicular Cancer Study Group Relapsed or Cisplatin-Refractory Germ Cell Cancer November 2006 Phase 2
    NCT01158222 Case Comprehensive Cancer Center Clear Cell Renal Cell Carcinoma|Stage IV Renal Cell Cancer August 18, 2010 Phase 2
    NCT00089648 Pfizer Carcinoma, Renal Cell December 2004 Phase 2
    NCT03091192 AstraZeneca|Hutchinson MediPharma (HMP) Carcinoma|Carcinoma, Renal Cell|Kidney Neoplasms|Urologic Neoplasms|Kidney Diseases|Neoplasms by Site|Enzyme Inhibitors|Protein Kinase Inhibitors May 17, 2017 Phase 3
    NCT00849186 Roswell Park Cancer Institute|National Cancer Institute (NCI) Kidney Cancer August 2007
    NCT00428597 Pfizer Carcinoma, Islet Cell|Carcinoma, Pancreas June 2007 Phase 3
    NCT00730353 Hoosier Cancer Research Network|Pfizer Esophageal Cancer August 2008 Phase 2
    NCT00265317 Pfizer Carcinoma, Non-Small-Cell Lung June 2006 Phase 2
    NCT00137423 Pfizer Carcinoma, Renal Cell Metastasis May 2005 Phase 2
    NCT01164228 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Kidney Cancer June 2010 Phase 2
    NCT01984242 Hoffmann-La Roche Renal Cell Carcinoma January 31, 2014 Phase 2
    NCT00570908 Baylor Breast Care Center Breast Cancer February 2009 Phase 2
    NCT00541008 UNICANCER|National Cancer Institute (NCI) Kidney Cancer September 2007 Phase 2
    NCT00748358 Assistance Publique - Hôpitaux de Paris Prostatic Neoplasms|Neoplasms, Hormone-Dependent|Tumor Markers, Biological|Survival Rate|Disease-Free Survival March 2008 Phase 2
    NCT01258348 Eli Lilly and Company Metastatic Renal Cell Cancer July 2008 Phase 1
    NCT00417677 Wyeth is now a wholly owned subsidiary of Pfizer Renal Cell Carcinoma March 2007 Phase 1|Phase 2
    NCT00979966 Central European Society for Anticancer Drug Research Non-clear Cell Renal Cell Cancer July 2009 Phase 2
    NCT00792025 Institut Curie|National Cancer Institute (NCI) Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter December 2008 Phase 2
    NCT00573404 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Gastrointestinal Stromal Tumor July 2007 Phase 1
    NCT00435409 Pfizer Breast Neoplasms February 2007 Phase 3
    NCT00411151 Johannes Gutenberg University Mainz|Pfizer Gastric Adenocarcinoma|Barrett Esophagus December 2006 Phase 2
    NCT00748163 Masonic Cancer Center, University of Minnesota Lung Cancer August 2008 Phase 2
    NCT00599924 Pfizer Colorectal Neoplasms|Neoplasms September 2005 Phase 1
    NCT00923117 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Glioblastoma Multiforme|Malignant Gliomas|Anaplastic Gliomas June 2008 Phase 2
    NCT00400114 University Health Network, Toronto|Pfizer Esophageal Cancer September 25, 2006 Phase 2
    NCT01118351 Case Comprehensive Cancer Center|Pfizer Recurrent Bladder Cancer|Transitional Cell Carcinoma of the Bladder October 2008 Phase 2
    NCT02230176 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France|Advanced Accelerator Applications Pancreatic Neuroendocrine Carcinoma February 2015 Phase 2
    NCT00891878 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer August 2009 Phase 2
    NCT00553696 Pfizer Stomach Neoplasms November 2007 Phase 1
    NCT00434226 Genentech, Inc. Non-Small Cell Lung Cancer March 2007 Phase 2
    NCT01371201 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France|ENSAT-CANCER European Network for the Study of Adrenal Tumours Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) December 2011 Phase 2
    NCT00859339 Noah Hahn, M.D.|Pfizer|Hoosier Cancer Research Network Transitional Cell Carcinoma of the Bladder March 2009 Phase 2
    NCT00555620 Pfizer Stomach Neoplasms May 2008 Phase 1
    NCT02570789 Jean-Pascal Machiels|Cliniques universitaires Saint-Luc- Université Catholique de Louvain Clear-cell Metastatic Renal Cell Carcinoma December 2012 Phase 4
    NCT02811861 Eisai Inc. Renal Cell Carcinoma October 13, 2016 Phase 3
    NCT00499135 National Cancer Institute (NCI) Adult Solid Neoplasm|Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer May 22, 2007 Phase 1
    NCT02761057 National Cancer Institute (NCI) Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma April 5, 2016 Phase 2
    NCT01026337 Abramson Cancer Center of the University of Pennsylvania Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer April 2009
    NCT00434356 Genentech, Inc. Metastatic Breast Cancer March 2007 Phase 2
    NCT00709995 Eli Lilly and Company Metastatic Renal Cell Carcinoma June 2008 Phase 2
    NCT00943839 Centre Antoine Lacassagne Kidney Cancer February 2009
    NCT00732914 Sponsor GmbH|iOMEDICO AG Renal Cell Carcinoma January 2009 Phase 3
    NCT00471328 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors March 2007 Phase 3
    NCT02944617 City of Hope Medical Center|National Cancer Institute (NCI) Diarrhea|Metastatic Renal Cell Cancer|Stage IV Renal Cell Cancer October 2016
    NCT00113516 Pfizer Non-small Cell Lung Cancer September 2005 Phase 2
    NCT01396408 Canadian Cancer Trials Group Advanced Rare Tumours July 14, 2011 Phase 2
    NCT00555672 Pfizer Stomach Neoplasms August 2008 Phase 1
    NCT00616122 University of California, San Francisco|National Cancer Institute (NCI) Breast Cancer March 2006 Phase 1|Phase 2
    NCT00953459 European Organisation for Research and Treatment of Cancer - EORTC Lung Cancer February 2009 Phase 2
    NCT01118039 Hospital del Mar|National Cancer Institute (NCI) Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer July 2006 Phase 2
    NCT00626509 Gruppo Italiano Carcinoma Renale|National Cancer Institute (NCI) Kidney Cancer February 2008 Phase 2
    NCT02401815 Plexxikon Gastrointestinal Stromal Tumors March 2015 Phase 1|Phase 2
    NCT00513695 University of Washington|National Cancer Institute (NCI) Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer June 2007 Phase 2
    NCT01216371 Association of Urogenital Oncology (AUO)|University Hospital, Essen Renal Cell Carcinoma|Pulmonary Metastases October 2010 Phase 2
    NCT00226811 Pfizer Stomach Neoplasms January 2006 Phase 2
    NCT00930345 Assistance Publique - Hôpitaux de Paris|Pfizer|National Cancer Institute, France Metastatic Renal Cell Carcinoma December 2008 Phase 4
    NCT02315625 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neuroendocrine Tumors December 5, 2014 Phase 2
    NCT03141177 Bristol-Myers Squibb Renal Cell Carcinoma July 10, 2017 Phase 3
    NCT00617253 Novo Nordisk A/S Cancer|Renal Cell Carcinoma July 12, 2007 Phase 2
    NCT01829841 Jiangsu HengRui Medicine Co., Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences Renal Cell Cancer|Metastatic Renal Cell Cancer May 2011 Phase 2
    NCT00537056 Stanford University|National Comprehensive Cancer Network Kidney Neoplasms|Carcinoma, Renal Cell|Kidney (Renal Cell) Cancer October 2007
    NCT00491738 Genentech, Inc. Renal Cell Carcinoma August 2007 Phase 2
    NCT00457392 Pfizer Carcinoma, Non-Small Cell Lung July 2007 Phase 3
    NCT00373256 Pfizer Breast Neoplasms November 2006 Phase 3
    NCT01664182 National Cancer Institute (NCI) Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer August 1, 2012 Phase 2
    NCT00861419 Amgen Advanced Solid Tumors December 2005 Phase 1
    NCT00482755 NCIC Clinical Trials Group|Canadian Cancer Trials Group Breast Cancer March 2007 Phase 2
    NCT00717587 Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI) Kidney Cancer June 2008 Phase 2
    NCT00915993 University of Pennsylvania|National Cancer Institute (NCI) Kidney Cancer May 2009
    NCT00700258 Pfizer Carcinoma, Renal Cell, Advanced|Lymphoma, Mantle-Cell|Gastrointestinal Stroma Tumors January 7, 2013
    NCT00489944 San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI) Intraocular Melanoma May 2007 Phase 2
    NCT00705874 Progen Pharmaceuticals Cancer May 2006 Phase 1
    NCT00936832 Federation Francophone de Cancerologie Digestive Colorectal Cancer|Metastatic Cancer April 2009 Phase 2
    NCT00463060 Icahn School of Medicine at Mount Sinai|Pfizer Cancer January 2007 Phase 1|Phase 2
    NCT02535351 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Clear-cell Metastatic Renal Cell Carcinoma November 2015 Phase 3
    NCT00457691 Pfizer Metastatic Colorectal Cancer June 2007 Phase 3
    NCT00734851 Duke University|Pfizer|Sanofi Prostate Cancer December 2008 Phase 2
    NCT00543504 M.D. Anderson Cancer Center Advanced Cancer October 2007 Phase 1
    NCT01381601 GlaxoSmithKline Carcinoma, Renal Cell March 2011
    NCT02208128 Heidelberg University Renal Cell Carcinoma May 2014
    NCT02688491 First Affiliated Hospital, Sun Yat-Sen University|Health Science Center of Xi’an Jiaotong University|Yantai Yuhuangding Hospital|Sun Yat-sen University Renal Neoplasms|Targeted Molecular Therapy July 2016
    NCT00444795 Pfizer Gastrointestinal Stromal Tumors May 2007
    NCT02959554 AIO-Studien-gGmbH|Bristol-Myers Squibb Metastatic Renal Cell Carcinoma November 2016 Phase 2
    NCT01381614 GlaxoSmithKline Carcinoma, Renal Cell March 2011
    NCT00619268 Centre Leon Berard Metastatic Renal Cell Carcinoma February 2008 Phase 2
    NCT03170180 Samsung Medical Center Stomach Neoplasms March 1, 2017 Phase 2
    NCT02960906 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie Clear Cell Metastatic Renal Cell Carcinoma March 2017 Phase 2
    NCT01254864 M.D. Anderson Cancer Center|Bristol-Myers Squibb|Janssen Scientific Affairs, LLC|Pfizer Prostate Cancer March 2011 Phase 2
    NCT02848768 Rennes University Hospital Metastatic Clear Cell Renal Cell Carcinoma December 2014
    NCT01449825 GlaxoSmithKline Carcinoma, Renal Cell December 2010
    NCT02264665 Pfizer|Novartis|Keyrus Biopharma Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive May 12, 2015
    NCT01190241 VU University Medical Center|VitrOmics BV Advanced Solid Tumors|Inoperable|Metastasis August 2010
    NCT02380625 Clinical Research Management, Inc.|Bill and Melinda Gates Foundation|Duke University|University of Sierra Leone|INC Research|University of North Carolina Ebola Virus Disease April 2015 Phase 1|Phase 2
    NCT00495872 M.D. Anderson Cancer Center Solid Tumors June 2007 Phase 1
    NCT00891475 Kidney Cancer Research Bureau Carcinoma, Renal Cell May 2008 Phase 1|Phase 2
    NCT02239952 VU University Medical Center Cancer|High-grade Glioma November 2014
    NCT01620216 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia May 2012 Phase 2
    NCT01306045 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic January 21, 2011 Phase 2
    NCT02068170 Katholieke Universiteit Leuven|Agentschap voor Innovatie door Wetenschap en Technologie Delirium|QT-prolongation February 2014
    NCT01502228 Indiana University Renal Cell Carcinoma October 2011
    NCT01441388 Pfizer Carcinoma, Renal Cell|Glioblastoma|Carcinoma, Hepatocellular December 2011 Phase 1
    NCT02013089 Sun Yat-sen University Gastrointestinal Cancers December 2013
    NCT02560012 The University of Texas Health Science Center, Houston Carcinoma, Renal Cell December 2015 Phase 2
    NCT02616185 Pfizer Prostatic Neoplasms December 30, 2015 Phase 1
    NCT02779283 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Untreated Adult Acute Myeloid Leukemia December 2015 Phase 1
    NCT02483247 Boston Biomedical, Inc Cancer September 2015 Phase 1|Phase 2
    NCT02693535 American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors March 2016 Phase 2
    NCT02465060 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cer August 12, 2015 Phase 2
    NCT01636908 VU University Medical Center Cancer|Advanced Solid Tumors August 2011
    NCT00668811 Washington Hospital Center|Pfizer Papillary Thyroid Cancer|Follicular Thyroid Cancer|Differentiated Thyroid Cancer April 2008 Phase 2
    NCT00873210 Pfizer Advanced or Metastatic Renal Cell Carcinoma|Renal Cancer May 2009
    NCT00864721 US Oncology Research|Pfizer Non Small Cell Lung Cancer February 2009 Phase 2
    NCT00684645 Pfizer Metastatic Renal Cell Carcinoma June 2008
    NCT00777478 Radboud University Colorectal Cancer December 2008 Phase 1
    NCT00460798 Pfizer Renal Cell Carcinoma February 2007 Phase 4
    NCT01215578 Assistance Publique - Hôpitaux de Paris Neuroendocrine Tumors|Pancreatic Neoplasms|Advanced Disease|Sunitinib October 2008 Phase 2
    NCT01917214 Pfizer Metastatic Renal Cell Carcinoma August 2013
    NCT00905021 Baylor Breast Care Center|Pfizer Metastatic Breast Cancer March 2010 Phase 1|Phase 2
    NCT00393796 University of Michigan Cancer Center|Pfizer Bladder Cancer May 2006 Phase 2
    NCT01215565 Assistance Publique - Hôpitaux de Paris Hepatocellular Carcinoma|Fibrolamellar Hepatocellular Carcinoma October 2009 Phase 2
    NCT00130897 Pfizer Carcinoma, Renal Cell July 2005
    NCT00094029 Pfizer Gastrointestinal Neoplasm September 2004
    NCT01731158 Central European Society for Anticancer Drug Research Metastatic Renal Cell Carcinoma October 2012 Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 2.5096 mL 12.5480 mL 25.0960 mL
    5 mM 0.5019 mL 2.5096 mL 5.0192 mL
    10 mM 0.2510 mL 1.2548 mL 2.5096 mL
    Kinase Assay
    [2]

    Biochemical assays to determine the activity of Sunitinib against different protein kinases are performed. Ki values for SU11248 against Flk-1, PDGFRβ, and FGFR1 are determined using glutathione S-transferase-fusion proteins containing the complete cytoplasmic domain of the RTK. Cellular assays to directly determine the ability of SU11248 to inhibit ligand-dependent RTK phosphorylation or cell proliferation and mitogenic responses are performed using serum-starved cells stimulated with 40 ng/mL VEGF165 (Flk-1/KDR), 0.5 μg/mL basic FGF (FGFR), or 50 ng/mL PDGF-AA (PDGFRα) or PDGF-BB (PDGFRβ)[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [3]

    Sunitinib (SU11248) is dissolved in DMSO and stored, and then diluted with appropriate media before use[3].

    RS4;11 and MV4;11 cell lines are starved overnight in medium containing 0.1% FBS prior to addition of SU11248 (1 nM, 5 nM, 10 nM, 25 nM, 75 nM, 100 nM, 250 nM, 500 nM) and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay in triplicate for each condition, as described by the manufacturer. Trypan blue cell viability assays are performed in parallel and yielded similar results[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2][4]

    Sunitinib (SU11248) is prepared as a carboxymethyl cellulose suspension (Mice)[2].

    Mice[2]
    Female nu/nu mice (8-12 weeks old, 25 grams) are used. Briefly, 3-5×106 tumor cells are implanted s.c. into the hind flank region of mice on day 0. Daily treatment of tumor-bearing mice with oral administration of SU11248 as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution is initiated once the tumors reached the indicated average size. Tumor growth is evaluated based on twice-weekly measurement of tumor volume. Typically, studies are terminated when tumors in vehicle-treated animals reach an average size of 1000 mm3 or when the tumors are judged to adversely effect the well being of the animals.
    Rat[4]
    Adult male Wistar rats (325-349 g) are used. To validate the ability of the time-lapse imaging method to evaluate the anti-angiogenic effects for a given drug treatment, two drug studies are conducted. In the first study, mesenteric windows are harvested from adult male Wistar rats and cultured for 3 days according to the two experimental groups: 1) 10% serum (n=8 tissues from 4 rats), and 2) 10% serum+Sunitinib (5 μM; n=8 tissues from 4 rats). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    398.47

    Formula

    C₂₂H₂₇FN₄O₂

    CAS No.

    557795-19-4

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: 25 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.56%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Sunitinib
    Cat. No.:
    HY-10255A
    Quantity: